{"id":53341,"date":"2023-01-26T16:02:51","date_gmt":"2023-01-26T15:02:51","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/drug-device-combination-product-market-analysis-report-2022-global-size-share-outlook-and-opportunity-forecasts-to-2028-researchandmarkets-com\/"},"modified":"2023-01-26T16:02:51","modified_gmt":"2023-01-26T15:02:51","slug":"drug-device-combination-product-market-analysis-report-2022-global-size-share-outlook-and-opportunity-forecasts-to-2028-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/drug-device-combination-product-market-analysis-report-2022-global-size-share-outlook-and-opportunity-forecasts-to-2028-researchandmarkets-com\/","title":{"rendered":"Drug Device Combination Product Market Analysis Report 2022 – Global Size, Share, Outlook, and Opportunity Forecasts to 2028 – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Drug Device Combination Product Market, By Products Type, By Application, By End-User, and By Geography – Size, Share, Outlook, and Opportunity Analysis, 2022 – 2028”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nCombination products are therapeutic and diagnostic products that combine drugs, devices and\/or biological products, leading to safer and more effective treatments. Combination products include at least two products, one, of medical device and other of drugs that work in coordination to treat. Thus, there is an increase in demand for drug device combination products.\n<\/p>\n

\nMarket Dynamics:<\/strong>\n<\/p>\n

\nRise in burden of chronic disorders, growing geriatric population, favorable government policies or initiatives to ensure patient safety, the outbreak of COVID-19 (pandemic), and the introduction of novel products by market players are major factors expected to drive growth of the global drug device combination product market over the forecast period.\n<\/p>\n

\nFor instance, according to the Centers for Disease Control and Prevention (CDC), 6 in 10 people in the United States live with at least one chronic disease, such as heart disease and stroke, cancer, or diabetes. These and other chronic diseases are the leading causes of death and disability in the U.S., and they are also a leading driver of health care costs.\n<\/p>\n

\nMoreover, in October 2020, Medtronic received the U.S. Food and Drug Administration (FDA) approval for the Abre Venous Self-Expanding Stent System. The system is indicated for use in the iliofemoral veins in patients with symptomatic iliofemoral venous outflow obstruction.\n<\/p>\n

\nKey Features of the Study:<\/strong>\n<\/p>\n